RS65302B1 - Oralne formulacije inhibitora srčanog sarkomera - Google Patents
Oralne formulacije inhibitora srčanog sarkomeraInfo
- Publication number
- RS65302B1 RS65302B1 RS20240236A RSP20240236A RS65302B1 RS 65302 B1 RS65302 B1 RS 65302B1 RS 20240236 A RS20240236 A RS 20240236A RS P20240236 A RSP20240236 A RS P20240236A RS 65302 B1 RS65302 B1 RS 65302B1
- Authority
- RS
- Serbia
- Prior art keywords
- oral formulations
- cardiac sarcomere
- inhibitor oral
- inhibitor
- sarcomere
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000002235 sarcomere Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875358P | 2019-07-17 | 2019-07-17 | |
| PCT/US2020/042389 WO2021011808A1 (en) | 2019-07-17 | 2020-07-16 | Cardiac sarcomere inhibitor oral formulations |
| EP20753563.4A EP3999038B1 (en) | 2019-07-17 | 2020-07-16 | Cardiac sarcomere inhibitor oral formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65302B1 true RS65302B1 (sr) | 2024-04-30 |
Family
ID=71995104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240236A RS65302B1 (sr) | 2019-07-17 | 2020-07-16 | Oralne formulacije inhibitora srčanog sarkomera |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220265612A1 (sr) |
| EP (1) | EP3999038B1 (sr) |
| JP (1) | JP2022542804A (sr) |
| KR (1) | KR20220082804A (sr) |
| CN (1) | CN114765954B (sr) |
| AU (1) | AU2020315642A1 (sr) |
| BR (1) | BR112022000495A2 (sr) |
| CA (1) | CA3144972A1 (sr) |
| CL (1) | CL2022000108A1 (sr) |
| DK (1) | DK3999038T3 (sr) |
| ES (1) | ES2974542T3 (sr) |
| FI (1) | FI3999038T3 (sr) |
| HR (1) | HRP20240200T1 (sr) |
| HU (1) | HUE065712T2 (sr) |
| IL (1) | IL289884A (sr) |
| LT (1) | LT3999038T (sr) |
| MX (1) | MX2022000708A (sr) |
| PL (1) | PL3999038T3 (sr) |
| PT (1) | PT3999038T (sr) |
| RS (1) | RS65302B1 (sr) |
| SI (1) | SI3999038T1 (sr) |
| TW (1) | TW202116307A (sr) |
| WO (1) | WO2021011808A1 (sr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020014428A2 (pt) | 2018-01-19 | 2020-12-01 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco |
| US11964967B2 (en) | 2018-06-26 | 2024-04-23 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| KR20210068422A (ko) | 2018-08-31 | 2021-06-09 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| JP2024508526A (ja) | 2021-03-04 | 2024-02-27 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| TW202320763A (zh) | 2021-07-16 | 2023-06-01 | 美商胞質動力學公司 | 治療肥厚性心肌病之方法 |
| US20240091203A1 (en) | 2022-07-20 | 2024-03-21 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| US20240115554A1 (en) | 2022-08-04 | 2024-04-11 | Cytokinetics, Incorporated | Methods for treating obstructive hypertrophic cardiomyopathy |
| WO2024179422A1 (zh) * | 2023-03-02 | 2024-09-06 | 苏州科睿思制药有限公司 | Aficamten的共晶及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007027855A2 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| PE20121478A1 (es) * | 2009-09-18 | 2012-11-12 | Sanofi Sa | Formulaciones en comprimido de teriflunomida: "(4'-trifluorometilfenil) amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada |
| US9199945B2 (en) * | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| WO2017059191A1 (en) * | 2015-09-30 | 2017-04-06 | Quartet Medicine, Inc. | Heteroaryl derivatives as sepiapterin reductase inhibitors |
| BR112020014428A2 (pt) | 2018-01-19 | 2020-12-01 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco |
-
2020
- 2020-07-16 SI SI202030397T patent/SI3999038T1/sl unknown
- 2020-07-16 AU AU2020315642A patent/AU2020315642A1/en active Pending
- 2020-07-16 RS RS20240236A patent/RS65302B1/sr unknown
- 2020-07-16 TW TW109124113A patent/TW202116307A/zh unknown
- 2020-07-16 CN CN202080062806.7A patent/CN114765954B/zh active Active
- 2020-07-16 EP EP20753563.4A patent/EP3999038B1/en active Active
- 2020-07-16 FI FIEP20753563.4T patent/FI3999038T3/fi active
- 2020-07-16 DK DK20753563.4T patent/DK3999038T3/da active
- 2020-07-16 BR BR112022000495A patent/BR112022000495A2/pt unknown
- 2020-07-16 MX MX2022000708A patent/MX2022000708A/es unknown
- 2020-07-16 HU HUE20753563A patent/HUE065712T2/hu unknown
- 2020-07-16 ES ES20753563T patent/ES2974542T3/es active Active
- 2020-07-16 WO PCT/US2020/042389 patent/WO2021011808A1/en active Application Filing
- 2020-07-16 KR KR1020227003543A patent/KR20220082804A/ko unknown
- 2020-07-16 JP JP2022502218A patent/JP2022542804A/ja active Pending
- 2020-07-16 PT PT207535634T patent/PT3999038T/pt unknown
- 2020-07-16 CA CA3144972A patent/CA3144972A1/en active Pending
- 2020-07-16 HR HRP20240200TT patent/HRP20240200T1/hr unknown
- 2020-07-16 PL PL20753563.4T patent/PL3999038T3/pl unknown
- 2020-07-16 LT LTEPPCT/US2020/042389T patent/LT3999038T/lt unknown
- 2020-07-16 US US17/627,600 patent/US20220265612A1/en active Pending
-
2022
- 2022-01-15 CL CL2022000108A patent/CL2022000108A1/es unknown
- 2022-01-16 IL IL289884A patent/IL289884A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL289884A (en) | 2022-03-01 |
| HUE065712T2 (hu) | 2024-06-28 |
| FI3999038T3 (fi) | 2024-02-21 |
| EP3999038A1 (en) | 2022-05-25 |
| WO2021011808A1 (en) | 2021-01-21 |
| LT3999038T (lt) | 2024-03-25 |
| EP3999038B1 (en) | 2024-01-10 |
| HRP20240200T1 (hr) | 2024-04-26 |
| PL3999038T3 (pl) | 2024-05-13 |
| DK3999038T3 (da) | 2024-03-18 |
| JP2022542804A (ja) | 2022-10-07 |
| TW202116307A (zh) | 2021-05-01 |
| ES2974542T3 (es) | 2024-06-27 |
| MX2022000708A (es) | 2022-02-23 |
| KR20220082804A (ko) | 2022-06-17 |
| BR112022000495A2 (pt) | 2022-03-03 |
| US20220265612A1 (en) | 2022-08-25 |
| CA3144972A1 (en) | 2021-01-21 |
| CL2022000108A1 (es) | 2022-10-21 |
| SI3999038T1 (sl) | 2024-05-31 |
| CN114765954A (zh) | 2022-07-19 |
| PT3999038T (pt) | 2024-03-14 |
| AU2020315642A1 (en) | 2022-03-03 |
| CN114765954B (zh) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289884A (en) | Oral formulations cardiac sarcomere inhibitors | |
| IL281075A (en) | Cardiac sarcomere inhibitors | |
| GB2592117B (en) | Oral solution cannabinoid formulations | |
| IL291942A (en) | Oral complement factor d inhibitors | |
| CA193365S (en) | Oral appliance | |
| CA193061S (en) | Toothbrush | |
| IL292682A (en) | Formulation of x842 for oral administration | |
| GB202117828D0 (en) | New formulations | |
| GB201904338D0 (en) | Fluorouracil-containing formulations | |
| IL283593A (en) | Bernaflam oral preparations | |
| PT4045038T (pt) | Novas formulações de 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida | |
| CA208705S (en) | Toothbrush | |
| CA206749S (en) | Oral appliance | |
| CA188766S (en) | Oral appliance | |
| IL290356A (en) | Formulations for Resotide | |
| IL284691A (en) | formulations | |
| CA193063S (en) | Toothbrush | |
| CA195883S (en) | Toothbrush | |
| GB202114564D0 (en) | Oral formulation | |
| CA192308S (en) | Toothbrush | |
| CA196019S (en) | Toothbrush | |
| CA196018S (en) | Toothbrush | |
| CA196017S (en) | Toothbrush | |
| GB201910092D0 (en) | New formulations | |
| GB201910093D0 (en) | New formulations |